- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06275724
Spesifisert narkotikabruksundersøkelse av Leqvio for s.c. Injeksjon.
Spesifisert narkotikabruksundersøkelse av Leqvio for s.c. Injeksjon (Familiær hyperkolesterolemi eller hyperkolesterolemi, CKJX839A11401)
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Uncontrolled, central registration system, multicenter, special drug use-results surveillance.
This is a prospective, open-label, multicenter, single-arm observational study (non-interventional study: NIS) conducted only in Japan.
The survey will include patients with familial hypercholesterolaemia or hypercholesterolaemia who have received treatment with Leqvio. Patients who discontinued treatment with Leqvio before completing the 24-month observation period will be followed for safety until the date of the last dose of Leqvio plus 180 days or until 24 months after the first dose of Leqvio, whichever comes earlier.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Akita, Japan, 0108577
- Novartis Investigative Site
-
Chiba, Japan, 2610024
- Novartis Investigative Site
-
Fukuoka, Japan, 8110213
- Novartis Investigative Site
-
Fukushima, Japan, 9601295
- Novartis Investigative Site
-
Himeji, Japan, 6711227
- Novartis Investigative Site
-
Ishikawa, Japan, 9208641
- Novartis Investigative Site
-
Kagoshima, Japan, 8920853
- Novartis Investigative Site
-
Kumamoto, Japan, 8614193
- Novartis Investigative Site
-
Kyoto, Japan, 6078062
- Novartis Investigative Site
-
Nara, Japan, 6308581
- Novartis Investigative Site
-
Okayama, Japan, 7008558
- Novartis Investigative Site
-
Osaka, Japan, 5458586
- Novartis Investigative Site
-
Osaka, Japan, 5438555
- Novartis Investigative Site
-
Osaka, Japan, 5588558
- Novartis Investigative Site
-
Shizuoka, Japan, 4228527
- Novartis Investigative Site
-
-
Aichi-ken
-
Handa, Aichi-ken, Japan, 4750817
- Novartis Investigative Site
-
Ichinomiya, Aichi-ken, Japan, 4918551
- Novartis Investigative Site
-
Ichinomiya, Aichi-ken, Japan, 4940001
- Novartis Investigative Site
-
Komaki, Aichi-ken, Japan, 4858520
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4540933
- Novartis Investigative Site
-
Nagoya, Aichi-ken, Japan, 4610045
- Novartis Investigative Site
-
Toyoake, Aichi-ken, Japan, 4701192
- Novartis Investigative Site
-
Tsushima, Aichi-ken, Japan, 4960038
- Novartis Investigative Site
-
-
Chiba
-
Asahi, Chiba, Japan, 2892511
- Novartis Investigative Site
-
Inzai, Chiba, Japan, 2701694
- Novartis Investigative Site
-
Urayasu, Chiba, Japan, 2790021
- Novartis Investigative Site
-
-
Ehime
-
Matsuyama, Ehime, Japan, 7918016
- Novartis Investigative Site
-
-
Fukui
-
Fukui-shi, Fukui, Japan, 9108526
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 8140180
- Novartis Investigative Site
-
Fukuoka, Fukuoka, Japan, 8150082
- Novartis Investigative Site
-
Kitakyushu, Fukuoka, Japan, 8078556
- Novartis Investigative Site
-
Kitakyushu, Fukuoka, Japan, 8000031
- Novartis Investigative Site
-
-
Fukushima
-
Fukushima, Fukushima, Japan, 9608611
- Novartis Investigative Site
-
Kōriyama, Fukushima, Japan, 9638501
- Novartis Investigative Site
-
Shirakawa, Fukushima, Japan, 9610005
- Novartis Investigative Site
-
-
Gifu
-
Gifu, Gifu, Japan, 5008384
- Novartis Investigative Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 7320053
- Novartis Investigative Site
-
Kure, Hiroshima, Japan, 7370023
- Novartis Investigative Site
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan, 0788211
- Novartis Investigative Site
-
Asahikawa, Hokkaido, Japan, 0788214
- Novartis Investigative Site
-
Sapporo, Hokkaido, Japan, 065-0027
- Novartis Investigative Site
-
Sapporo, Hokkaido, Japan, 0040052
- Novartis Investigative Site
-
Sapporo, Hokkaido, Japan, 0620003
- Novartis Investigative Site
-
-
Hyōgo
-
Amagasaki, Hyōgo, Japan, 6608511
- Novartis Investigative Site
-
Himeji, Hyōgo, Japan, 6708560
- Novartis Investigative Site
-
Kobe, Hyōgo, Japan, 6540026
- Novartis Investigative Site
-
Ono, Hyōgo, Japan, 6751327
- Novartis Investigative Site
-
Takarazuka, Hyōgo, Japan, 6650873
- Novartis Investigative Site
-
-
Ibaraki
-
Kamisu, Ibaraki, Japan, 3140146
- Novartis Investigative Site
-
Koga, Ibaraki, Japan, 3060232
- Novartis Investigative Site
-
Mito, Ibaraki, Japan, 3100015
- Novartis Investigative Site
-
Moriya, Ibaraki, Japan, 3020102
- Novartis Investigative Site
-
Tsukuba, Ibaraki, Japan, 3058576
- Novartis Investigative Site
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japan, 8908760
- Novartis Investigative Site
-
-
Kanagawa
-
Fujisawa, Kanagawa, Japan, 2520802
- Novartis Investigative Site
-
Yokohama, Kanagawa, Japan, 2248503
- Novartis Investigative Site
-
Yokohama, Kanagawa, Japan, 2350016
- Novartis Investigative Site
-
Yokosuka, Kanagawa, Japan, 2398567
- Novartis Investigative Site
-
Yokosuka, Kanagawa, Japan, 2400101
- Novartis Investigative Site
-
-
Kumamoto
-
Yatsushiro, Kumamoto, Japan, 8668533
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 6028566
- Novartis Investigative Site
-
Kyoto, Kyoto, Japan, 6128555
- Novartis Investigative Site
-
Kyōtanabe, Kyoto, Japan, 6100334
- Novartis Investigative Site
-
-
Mie-ken
-
Tsu, Mie-ken, Japan, 5148507
- Novartis Investigative Site
-
-
Nagasaki
-
Nagasaki, Nagasaki, Japan, 8508555
- Novartis Investigative Site
-
Nagasaki, Nagasaki, Japan, 8528055
- Novartis Investigative Site
-
Ōmura, Nagasaki, Japan, 8568562
- Novartis Investigative Site
-
-
Nara
-
Ikoma, Nara, Japan, 6360802
- Novartis Investigative Site
-
Kashihara, Nara, Japan, 6340045
- Novartis Investigative Site
-
Tenri, Nara, Japan, 6328552
- Novartis Investigative Site
-
-
Niigata
-
Nagaoka, Niigata, Japan, 9408621
- Novartis Investigative Site
-
-
Oita Prefecture
-
Ōita, Oita Prefecture, Japan, 8700263
- Novartis Investigative Site
-
Ōita, Oita Prefecture, Japan, 8701133
- Novartis Investigative Site
-
Ōita, Oita Prefecture, Japan, 8797761
- Novartis Investigative Site
-
-
Okayama-ken
-
Kurashiki, Okayama-ken, Japan, 7108602
- Novartis Investigative Site
-
-
Okinawa
-
Urasoe, Okinawa, Japan, 9012102
- Novartis Investigative Site
-
Uruma, Okinawa, Japan, 9042293
- Novartis Investigative Site
-
-
Osaka
-
Izumisano, Osaka, Japan, 5988577
- Novartis Investigative Site
-
Moriguchi, Osaka, Japan, 5708507
- Novartis Investigative Site
-
Osaka, Osaka, Japan, 5400006
- Novartis Investigative Site
-
Osaka, Osaka, Japan, 5430042
- Novartis Investigative Site
-
Takatsuki, Osaka, Japan, 5698686
- Novartis Investigative Site
-
Takatsuki, Osaka, Japan, 5690852
- Novartis Investigative Site
-
Takatsuki, Osaka, Japan, 5691121
- Novartis Investigative Site
-
Toyonaka, Osaka, Japan, 5600083
- Novartis Investigative Site
-
-
Saitama
-
Asaka, Saitama, Japan, 3510021
- Novartis Investigative Site
-
Gyōda, Saitama, Japan, 3610056
- Novartis Investigative Site
-
Iruma-gun, Saitama, Japan, 3500495
- Novartis Investigative Site
-
Kitamoto, Saitama, Japan, 3648501
- Novartis Investigative Site
-
Sōka, Saitama, Japan, 3400043
- Novartis Investigative Site
-
Tokorozawa, Saitama, Japan, 3591142
- Novartis Investigative Site
-
-
Shiga
-
Nagahama, Shiga, Japan, 5268580
- Novartis Investigative Site
-
-
Shizuoka
-
Izunokuni, Shizuoka, Japan, 4102295
- Novartis Investigative Site
-
-
Tochigi
-
Mooka, Tochigi, Japan, 3214306
- Novartis Investigative Site
-
-
Tokyo
-
Hachiōji, Tokyo, Japan, 1920918
- Novartis Investigative Site
-
Machida, Tokyo, Japan, 1940021
- Novartis Investigative Site
-
Meguro City, Tokyo, Japan, 1538515
- Novartis Investigative Site
-
Minato, Tokyo, Japan, 1060031
- Novartis Investigative Site
-
Nerima-ku, Tokyo, Japan, 1768530
- Novartis Investigative Site
-
Shinjuku, Tokyo, Japan, 1608488
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Japan, 1628666
- Novartis Investigative Site
-
Sumida City, Tokyo, Japan, 1308575
- Novartis Investigative Site
-
Toshima-ku, Tokyo, Japan, 1710014
- Novartis Investigative Site
-
-
Toyama
-
Takaoka, Toyama, Japan, 9391104
- Novartis Investigative Site
-
-
Wakayama
-
Hashimoto, Wakayama, Japan, 6480005
- Novartis Investigative Site
-
-
Yamagata
-
Sakata, Yamagata, Japan, 9988501
- Novartis Investigative Site
-
Yamagata, Yamagata, Japan, 9909585
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients treated with inclisiran
Beskrivelse
Inclusion Criteria:
- Patients who provided written informed consent to participate in this survey prior to the start of treatment with Leqvio.
- Patients who received treatment with Leqvio as per the package insert.
Exclusion Criteria:
- Patients who received treatment with a formulation containing the same ingredients as Leqvio in the past.
- Patients participating in other interventional studies at the time of informed consent.
- Patients planning to participate in other interventional studies during this survey.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
inclisiran
Patients prescribed with inclisiran |
Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with adverse events
Tidsramme: Up to 24 months
|
To evaluate the long-term safety profile of Leqvio |
Up to 24 months
|
|
Numbers of patients with serious adverse events, adverse events by severity, and adverse drug reactions
Tidsramme: Up to 24 months
|
To evaluate the long-term safety profile of Leqvio |
Up to 24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of patients with adverse events leading to discontinuation of treatment with the product
Tidsramme: Up to 24 months
|
To evaluate the tolerability of Leqvio |
Up to 24 months
|
|
Percent change from baseline in LDL-C levels
Tidsramme: Month 24
|
To evaluate the efficacy of Leqvio based on LDL-C levels |
Month 24
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Metabolisme, medfødte feil
- Genetiske sykdommer, medfødte
- Metabolske sykdommer
- Hyperlipidemier
- Dyslipidemier
- Lipidmetabolismeforstyrrelser
- Lipidmetabolisme, medfødte feil
- Hyperlipoproteinemier
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Ernæringsmessige og metabolske sykdommer
- Homozygot familiær hyperkolesterolemi
- Hyperkolesterolemi
- Hyperlipoproteinemi type II
- Aln-PCS
Andre studie-ID-numre
- CKJX839A11401
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .